Scientific deep-dive

Tirzepatide vs GLP-1s for Heart Outcomes: What Meta-Analyses Show

Pooled analyses have not shown that tirzepatide protects the heart better than GLP-1 drugs. Here is what each meta-analysis compared, why their answers differ, and how conflicting real-world studies fit in.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
9 min read·20 citations

Meta-analyses don’t yet show that tirzepatide protects the heart better than GLP-1 drugs. The most direct pooled comparison, one randomized trial plus seven observational studies, found a hazard ratio of 0.85 for major adverse cardiovascular events (MACE; 95% CI 0.70 to 1.04), which is not statistically significant, with heterogeneity of 90.4%.[3] Reviews that compare each drug with placebo often favor tirzepatide, but they answer a different question and rest mostly on indirect evidence.[5]

About this article

This page compares pooled analyses. For the trial itself, see our SURPASS-CVOT deep dive; for death from any cause, see does tirzepatide help you live longer? Much of the evidence comes from people with type 2 diabetes, heart disease or both, so results may not apply to someone taking these drugs only for weight.

The one large randomized comparison

SURPASS-CVOT is the anchor for most of this literature. It randomized 13,299 adults with type 2 diabetes and atherosclerotic disease to tirzepatide (up to 15 mg) or dulaglutide 1.5 mg, with 13,165 in the modified intention-to-treat analysis. MACE occurred in 12.2% and 13.1% (HR 0.92, 95.3% CI 0.83 to 1.01). Tirzepatide met noninferiority (P=0.003) and missed superiority (P=0.09). Eli Lilly, which makes tirzepatide and dulaglutide, funded it.[1]

A later post hoc analysis used a broader six-part cardiorenal composite that included all-cause death, revascularization, heart failure hospitalization and kidney outcomes. That composite occurred in 23.7% and 27.4% (HR 0.84, 95% CI 0.79 to 0.90).[2] Because it was defined after the fact, it supports further study and doesn’t overturn the primary result. A network meta-analysis of tirzepatide and dulaglutide doses added little independent information: 13,165 of its 14,348 participants came from this one trial, and it found no significant differences in mortality or major cardiovascular events.[4]

Eight reviews, and the question each one asked

These analyses overlap and aren’t interchangeable, since each has its own comparator and population. In table order, they are Silva 2026,[3] Shokravi 2026,[5] Abomohsen 2026,[6] Silverii 2026,[7] Spiazzi 2026,[8] Chuang 2026,[9] Nong 2026[10] and Damen 2026.[11]

Pooled analyses touching tirzepatide and cardiovascular outcomes. Comparators differ, so read across with care.
ReviewEvidence and populationComparisonMain finding
Silva 20268 studies (1 randomized, 7 observational), 323,439 patients; overweight or obesityTirzepatide vs GLP-1 drugsMACE HR 0.85 (0.70 to 1.04); all-cause death HR 0.90 (0.79 to 1.02); cardiovascular death HR 0.88 (0.76 to 1.00)
Shokravi 202611 randomized trials, 1 of tirzepatide; type 2 diabetes with heart disease or high riskNetwork, each drug vs placebo and vs each otherAgent level: MACE HR 0.81 (0.70 to 0.94) vs placebo and 0.79 (0.65 to 0.97) vs lixisenatide; no significant difference vs semaglutide or dulaglutide
Abomohsen 202611 randomized trials, 83,215 people; same populationNetwork vs placeboStroke RR 0.71 (0.54 to 0.93) with tirzepatide; no regimen significantly reduced all-cause or cardiovascular death
Silverii 202693 randomized trials of at least 40 weeks; type 2 diabetesNetwork vs placeboTirzepatide: MACE OR 0.82 (0.72 to 0.93), death 0.72 (0.64 to 0.82). GLP-1 class: MACE 0.87 (0.83 to 0.92), death 0.85 (0.80 to 0.91)
Spiazzi 202622 randomized trials, 29,023 people; type 2 diabetes or overweight/obesityTirzepatide vs trial controls, fixed-effectsMACE OR 0.87 (0.79 to 0.94); all-cause death OR 0.84 (0.75 to 0.93); no association for individual MACE components or heart failure hospitalization
Chuang 202615 randomized trials, 97,173 people; type 2 diabetesNetwork of GLP-1-based drugsMost favorable for MACE: efpeglenatide, albiglutide, injectable semaglutide; most mortality comparisons not significant
Nong 2026 (BMJ)262 randomized trials, 99,791 people; overweight or obesityNetwork of 19 drugsOnly injectable semaglutide was tied to lower death (RR 0.81, 0.72 to 0.93), largely from outcome trials in high-risk people; heart failure risk lower with semaglutide (0.43) and tirzepatide (0.49)
Damen 2026 (ACP)69 randomized studies, 112,511 people; overweight or obesityPairwise and networkSemaglutide probably reduced death and MACE; evidence on these outcomes described as limited

Why the same trials give different answers

Tirzepatide’s outcome evidence leans on one trial. In the Shokravi network that single trial joined tirzepatide to everything else through dulaglutide, and the authors rated certainty for tirzepatide as low or very low.[5] They also describe their class-level contrast with GLP-1 drugs as hypothesis-generating, because a formal comparison wasn’t possible.[5]

Modeling choices can flip significance. In that same paper, all-cause death versus placebo was HR 0.74 (0.65 to 0.83) when GLP-1 drugs were pooled as a class, and HR 0.76 (0.56 to 1.03) when each drug stood alone. The authors explain that pooling narrows the confidence intervals by assuming similar effects across agents.[5] Using separate methods, the Abomohsen network found no regimen that significantly lowered death.[6]

Placebo comparisons are indirect. In Silverii, which rated certainty for tirzepatide moderate to high, tirzepatide’s estimates against placebo are numerically lower than the GLP-1 class’s, which isn’t the same as tirzepatide lowering risk more than those drugs.[7] Spiazzi rated its MACE finding high certainty, but the abstract doesn’t separate placebo from active controls, so it doesn’t isolate a GLP-1 comparison, and one author reports fees from Lilly.[8]

Mixing study types adds noise. Silva’s exploratory type 2 diabetes subgroup showed lower all-cause death (HR 0.85, 0.76 to 0.94) and heart failure (HR 0.75, 0.58 to 0.97). The authors still concluded that heterogeneity and the predominance of observational studies limit causal interpretation.[3] The abstract doesn’t list the included studies, so it doesn’t show which ones drive the result.

The imputed placebo estimate, and real placebo data

Because SURPASS-CVOT had no placebo arm, a Lilly-funded analysis estimated one by multiplying its result by dulaglutide’s result against placebo in REWIND, another Lilly-funded trial. That gave tirzepatide HR 0.72 (0.55 to 0.94) for MACE and HR 0.61 (0.45 to 0.82) for all-cause death.[12] The authors call it an indirect, prespecified exploratory comparison. About 80% of REWIND participants were excluded for not meeting SURPASS-CVOT criteria, and the two trials ran at different times with different background treatment.[12]

Trials that did use placebo are short on events. A review of 21 such trials (8,043 participants, searched to June 2025) found all-cause death OR 1.02 (0.57 to 1.81), which it labeled underpowered and very low certainty.[13] A Cochrane review in adults with obesity estimated MACE at RR 0.75 (0.34 to 1.66) at 12 to 18 months and noted that all nine included trials reported a major manufacturer role.[14] Those wide intervals fit benefit, no effect or harm, and the Cochrane authors read their MACE result as likely little to no difference, at moderate certainty.[14]

Real-world studies point in different directions

We found no randomized tirzepatide-versus-semaglutide trial built around heart events, so that comparison currently rests on observational data and indirect networks. These studies show association, and prescribing patterns can skew them. Their results conflict:

  • Type 2 diabetes with heart disease, commercial insurance data: compared with dulaglutide, tirzepatide was linked to lower modified MACE (HR 0.80, 0.65 to 0.99), driven by all-cause death. Compared with semaglutide, rates were similar (HR 1.03, 0.90 to 1.17).[15]
  • No diabetes, TriNetX records: tirzepatide was linked to fewer events than semaglutide at 12 months (1.90% vs 2.18%, HR 0.86, 0.77 to 0.97), mostly new heart failure, with no significant difference in death, acute coronary syndrome or stroke.[16] People with recent atherosclerotic events or prior heart failure were excluded.
  • Stratified by diabetes, TriNetX records: tirzepatide was linked to lower risk across outcomes. For heart failure at 1 year, the risk ratio against semaglutide was 0.82 with diabetes and 0.60 without.[17]
  • Established atherosclerotic disease, no diabetes, US claims: here semaglutide came out ahead, with HR 0.71 for revised 3-point MACE and HR 0.78 for 5-point. All seven authors were Novo Nordisk employees and shareholders at the time; Novo makes semaglutide.[18]

Heart rhythm adds another wrinkle. A network meta-analysis of 94 trials found fewer new atrial fibrillation diagnoses with injectable semaglutide than with tirzepatide (RR 0.57, 0.37 to 0.88), an indirect estimate that its authors say needs confirmation.[19]

What is still missing

Tirzepatide’s obesity outcomes trial, SURMOUNT-MMO, lists 15,374 participants and an estimated primary completion date of October 2027.[20] It is designed to test tirzepatide against placebo in obesity, the question semaglutide’s SELECT trial addressed for that drug. Its registered comparator is placebo, so it won’t test tirzepatide against a GLP-1 drug directly.[20] Shokravi and colleagues say head-to-head trials are needed to settle that question.[5]

What to raise with a prescriber

  • Which evidence matches you. Trial data for tirzepatide come mainly from people with type 2 diabetes and heart disease, and placebo-controlled obesity data remain thin.[1][14]
  • What you are treating. If heart protection is the priority and you don’t have diabetes, ask how the outcome data for semaglutide compare with the weight data for tirzepatide.[10][11]
  • How to read a real-world claim, including who funded it and whether the study population resembles you.[18]

Our reviews

Providers that offer tirzepatide

Telehealth providers we’ve reviewed. Each opens our full, independent review.

We may earn a commission from featured partners. Learn more

See the full ranking →

Frequently Asked Questions

That is not established. We found no randomized trial testing the two against each other for heart events. Observational studies conflict: one found similar rates, some favored tirzepatide, and a study by Novo Nordisk employees favored semaglutide. A network meta-analysis found no significant difference in major cardiovascular events between them.
Against placebo, several network and pooled analyses estimate fewer major cardiovascular events, but most of that evidence is indirect because the main outcomes trial, SURPASS-CVOT, compared tirzepatide with dulaglutide. In that trial tirzepatide was noninferior (hazard ratio 0.92) and missed superiority. One meta-analysis found no association for the individual components of major events.
It has not been shown clearly. The most direct pooled comparison estimated a hazard ratio of 0.90 with a confidence interval of 0.79 to 1.02, which crosses no difference, and most of its studies were observational. A subgroup with type 2 diabetes showed a lower estimate, but the authors called that analysis exploratory.
Not directly. SURMOUNT-MMO compares tirzepatide with placebo in adults with obesity, so it can show whether tirzepatide lowers events and deaths in that group. Any comparison with semaglutide’s SELECT trial would still be across trials, with different people and different eras.

References

  1. 1.Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025. PMID: 41406444.
  2. 2.Nissen SE, Wolski K, D'Alessio D, Weerakkody G, Kiljanski J, Wiese RJ, et al. Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 41903177.
  3. 3.Silva JPMRJ, Nogueira BV, Sartori DL, da Silva JRC, Sciota LBA, de Mendonça Bisneto OI, et al. Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis. Diabetes Obes Metab. 2026. PMID: 42410309.
  4. 4.Hageen AW, Gadelmawla AF, Saleh AO, Bahnasy S, Eladawi S, Abdelaziz M, et al. Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical Trials. Endocrinol Diabetes Metab. 2026. PMID: 42706739.
  5. 5.Shokravi A, Seth J, Mancini GBJ. Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis. Cardiovasc Diabetol. 2026. PMID: 41761267.
  6. 6.Abomohsen M, Rifai M, Gadelmawla AF, Alghzawi HM, Elgendy MS, Bakr HM, et al. Preferred Glucagon-like Peptide-1 Receptor Agonists in Adults With Type 2 Diabetes and Established Cardiovascular Disease or High Cardiovascular Risk: A Network Meta-analysis of Randomized Trials. Can J Diabetes. 2026. PMID: 41967797.
  7. 7.Silverii GA, Velardi V, Marinelli C, Lax A, Monami M, Mannucci E. Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis. Diabetes Obes Metab. 2026. PMID: 42530338.
  8. 8.Spiazzi BF, Zingano CP, Colpani V, Gerchman F. Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2026. PMID: 42442557.
  9. 9.Chuang SM, Liu SC, Chien KL, Lin CJ, Tsai MC, Shih HM. The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis. Diabetes Obes Metab. 2026. PMID: 42219271.
  10. 10.Nong K, Shi Q, Xie X, Wang Y, Agarwal A, Guyatt GH, et al. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ. 2026. PMID: 42419792.
  11. 11.Damen JAA, Idema DL, Vernooij RWM, Huis In 't Veld LF, Kusters MPT, Lokerse ME, et al. Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. Ann Intern Med. 2026. PMID: 42296503.
  12. 12.Sattar N, Gerstein HC, D'Alessio D, Bhatt DL, Buse JB, Del Prato S, et al. Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND. Diabetes Care. 2026. PMID: 41940793.
  13. 13.Sillassen CDB, Faltermeier P, Bjerg JL, Andersen RK, Petersen JJ, Andersen PB, et al. The adverse effects associated with tirzepatide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis. BMC Med. 2026. PMID: 41896878.
  14. 14.Franco JV, Guo Y, Varela LB, Aqra Z, Alhalahla M, Medina Rodriguez M, et al. Tirzepatide for adults living with obesity. Cochrane Database Syst Rev. 2025. PMID: 41161687.
  15. 15.Ostrominski JW, Ortega-Montiel J, Wexler DJ, Everett BM, Cromer SJ, Byrne CF, et al. Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations. Diabetes Care. 2026. PMID: 41778928.
  16. 16.Katsura M, Horiuchi Y, Tanabe K, Wettersten N. Real-World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non-Diabetic Adults. Diabetes Obes Metab. 2026. PMID: 41891334.
  17. 17.Azzam AY, Essibayi MA, Rai P, Salim HA, Alhasan MS, Anindo M, et al. Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation. JACC Adv. 2026. PMID: 42489387.
  18. 18.Wilson L, Zhao Z, Divino V, Bassan M, Hartaigh BÓ, Stensen S, et al. Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER). Diabetes Obes Metab. 2026. PMID: 41491349.
  19. 19.Barbosa LM, Rodrigues Oliveira VM, Ruelas MG, Nascimento BR, Moreira HG, Nunes MDCP, et al. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias: A Network Meta-Analysis. Heart Rhythm. 2026. PMID: 42933519.
  20. 20.Eli Lilly and Company. A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO) (NCT05556512). ClinicalTrials.gov. 2022. https://clinicaltrials.gov/study/NCT05556512

Trulicity vs Ozempic vs Mounjaro for T2D: Head-to-Head Evidence

Trulicity (dulaglutide), Ozempic (semaglutide), and Mounjaro (tirzepatide) are the three injectable GLP-1 / GIP-GLP-1 options for T2D. We walk through SUSTAIN-7, SURPASS-2, AWARD-11, and the practical prescribing differences.

11 min read

Do GLP-1 Drugs Lower Obesity-Related Cancer Risk? What Meta-Analyses Show

Observational reviews link GLP-1 drugs to lower rates of several obesity-related cancers, but a meta-analysis of 48 randomized trials found little or no clear effect. Why the evidence splits, and why the comparison drug changes the answer.

8 min read

GLP-1 Trial Results Q3 2026: Retatrutide TRIUMPH, Survodutide & Orforglipron ACHIEVE-4

Quarterly digest of GLP-1 and incretin trial results through mid-October 2026: retatrutide TRIUMPH-1 and TRIUMPH-2, survodutide SYNCHRONIZE, orforglipron ACHIEVE-4, Mounjaro's new cardiovascular indication, CagriSema under FDA review, and what comes next.

14 min read

Orforglipron and the Heart: The Lancet Cardiovascular Safety Trial

ACHIEVE-4 found orforglipron non-inferior to insulin glargine for major cardiovascular events in high-risk adults with type 2 diabetes. What the result shows, what it leaves open, and how far it applies to people taking Foundayo for weight.

8 min read

Does Tirzepatide Lower Atrial Fibrillation Risk? What a 2026 Meta-Analysis Found

A 2026 meta-analysis of 10 placebo-controlled trials found no clear link between tirzepatide and atrial fibrillation in either direction, plus a cautious signal for arrhythmia overall. Here is how that fits with class-level and observational data.

7 min read

GLP-1 and HFrEF Heart Failure: The Evidence (2026)

GLP-1 drugs help in HFpEF, but the randomized HFrEF trials (FIGHT, LIVE) of liraglutide showed no benefit, a faster heart rate, and possible harm signals.

12 min read

Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

7.1

AgelessRx

Longevity-focused GLP-1 care with microdosing and brand-name options

Read full review →

From $209/mo

microdose, 2-month plan rate

Get started →
7.2

HumeCare+

GLP-1 weight loss with real-time body-composition tracking to protect muscle

Read full review →

From $299/mo

Get started →
8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Read full review →

From $69/mo

+ required membership

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →